Document is current
Any future updates will be listed below
-
Authors
Mateo, Mathieu https://orcid.org/0000-0001-7941-0245
Reynard, Stéphanie https://orcid.org/0000-0002-8508-5167
Pietrosemoli, Natalia
Perthame, Emeline https://orcid.org/0000-0002-8266-5908
Journeaux, Alexandra
Noy, Kodie
Germain, Clara
Carnec, Xavier https://orcid.org/0000-0001-7858-1675
Picard, Caroline https://orcid.org/0000-0002-9214-3900
Borges-Cardoso, Virginie
Hortion, Jimmy
Lopez-Maestre, Hélène https://orcid.org/0000-0002-5125-9085
Regnard, Pierrick
Fellmann, Lyne
Vallve, Audrey
Barron, Stéphane
Jourjon, Ophélie
Lacroix, Orianne
Duthey, Aurélie
Dirheimer, Manon
Daniau, Maïlys
Legras-Lachuer, Catherine
Carbonnelle, Caroline
Raoul, Hervé https://orcid.org/0000-0002-4241-3255
Tangy, Frédéric https://orcid.org/0000-0002-5937-5654
Baize, Sylvain https://orcid.org/0000-0002-3234-7477
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-21-CE18-0004-01)
Coalition for Epidemic preparedness and Innovations
- License Information
-
More Information
Article History
Received: 17 October 2022
Accepted: 22 February 2023
First Online: 11 March 2023
Competing interests
: The authors declare that they have no competing interests. M.M., S.Bai, and F.T. are inventors of MeV-NP that is protected by US patent Lassa vaccine no. 20200308555.
